By:
On:
In: Essential Advice
With: 0 Comments

Any proper investment strategy should include an understanding of the tax implications. Both from your personal perspective For instance What tax rate are you incurring? And the perspective of the company you are investing in. For instance, what’s the effective tax rate of the company you are investing in? Finally, your choice of whether you prepare your own taxes or let a professional handle them is another decision you will have to make. With December 2016 fast approaching you need to approach and review your tax status as a priority. Some useful links: https://www.entrepreneur.com/article/225378 https://www.thebalance.com/new-york-personal-income-tax-3193284 Disclaimer We are not responsible for the accuracy of theseRead More →

By:
On:
In: Essential Advice
Tagged:
With: 0 Comments

Deutsche Bank AG (DB) gained over 12% on Friday as newspaper sources speculated that Deutsche will be able to negotiate a settlement with the Justice department in the $5-$8 Billion dollar range, as Deutsche has already reserved $5 Billion in its accounts this was welcome news. Whilst shares are unlikely to fully recover to the $15.26 of September 9th 2016, it’s not inconceivable that they could rise to a mid-level between $13.09 and $15.26 or $14.18 another 8% higher.However fundamental issues remain at the bank, it’s price would still be down from $24.15 at the beginning of the year or 37%. Given a potential gainRead More →

By:
On:
In: Essential Advice
With: 0 Comments

Progenics has an interesting pipeline and looks like it would be a good candidate for acquisition. Its corporate presentation is here: http://ir.progenics.com/ Highlights of the positive RECENT APPROVALS THAT WILL GENERATE REVENUE http://ir.valeant.com/news-releases/2016/07-19-2016-230453094 PHEOCHROMOCYTOMA AND PARAGANGLIOMA a 6 Million patient market Azedra in clinical studies, possible topline data by early 2017 and fast track FDA application thereafter Progen’s Pro 140 for HIV being commercialised by Cytodyn http://www.cytodyn.com/drug-pipeline/pro-140 PROSTATE CANCER Progenics has a series of products that are diagnostic and therapeutic, these are in phase 1 to 3 Also its diagnostics might be a good candidate for prostate cancer active surveillance, where prostate cancer is monitoredRead More →

By:
On:
In: Essential Advice
With: 0 Comments

Last week, we made a small investment in Huntsman Corp at $14.64. Over the week the shares are up over 7% mainly due to damage at a competitors plant that might result in a shortage of polyurethane chemicals in the Asian market. The shares have a decent dividend yield of over 3%. However projected margin pressure and decreased sales of 7% over the prior year has depressed the stock. Most analysts have a strong sell recommendation. Also 2015 results reflect negative cashflow and high debt levels could result in significant additional interest costs if interest rates rise in December 2016. However the company seems to beRead More →

By:
On:
In: Essential Advice
With: 0 Comments

GPIW Grand Perfecta Inc started as a Horse and race news service for Asia particularly the Japanese market. They have now created a fantasy sports service for Asia and their core business has changed. Using the values for Draft King, the share pricing according to some articles should be in the $2 to $3 range. The share price is already up 50% and we will be looking at the financials of the company in the next article.Read More →